<![CDATA[Dr Callahan on the Efficacy of ctDNA-Based Therapy Switch in ER+ Advanced Breast Cancer]]>
“There was an analysis of PFS2, which was difficult to interpret. But [the PFS2 data] provide some rationale to make [treatment] changes based on molecular findings or blood tests.” Rena D. Callahan, MD, a breast medical oncologist at UCLA Health and an …